iTeos Therapeutics, Inc.

Informe acción NasdaqGM:ITOS

Capitalización de mercado: US$557.1m

Salud financiera de hoja de balance de iTeos Therapeutics

Salud financiera controles de criterios 6/6

iTeos Therapeutics tiene un patrimonio de los accionistas total de $541.2M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $629.8M y $88.6M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$449.14m
PatrimonioUS$541.20m
Total pasivoUS$88.57m
Activos totalesUS$629.77m

Actualizaciones recientes sobre salud financiera

Recent updates

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough

Jan 25
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

Jan 10

Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%

May 13
Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%

Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding

Mar 21
Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding

The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically

Aug 12
The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically

iTeos Therapeutics GAAP EPS of $0.16 misses by $1.04

Aug 10

iTeos Therapeutics: Too Many Unknowns

Jul 27

News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts

May 11
News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts

Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic

Nov 25
Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic

We Think iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Drive Business Growth

Aug 24
We Think iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Drive Business Growth

iTeos Therapeutics: My Calculations Suggest Q3 Earnings Will Exceed $10 Per Share

Aug 15

GlaxoSmithKline - iTeos deal intensifies competition in anti-TIGIT space: Piper Sandler

Jun 15

We Think iTeos Therapeutics (NASDAQ:ITOS) Can Easily Afford To Drive Business Growth

Feb 07
We Think iTeos Therapeutics (NASDAQ:ITOS) Can Easily Afford To Drive Business Growth

Is iTeos Therapeutics, Inc. (NASDAQ:ITOS) Popular Amongst Institutions?

Dec 16
Is iTeos Therapeutics, Inc. (NASDAQ:ITOS) Popular Amongst Institutions?

iTeos Therapeutics EPS misses by $0.11

Nov 12

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($480.4M) de ITOS superan a sus pasivos a corto plazo ($35.6M).

Pasivo a largo plazo: Los activos a corto plazo de ITOS ($480.4M) superan a sus pasivos a largo plazo ($53.0M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: ITOS está libre de deudas.

Reducción de la deuda: ITOS no ha tenido ninguna deuda en los últimos 5 años.

Cobertura de la deuda: ITOS no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.

Cobertura de intereses: ITOS no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.


Hoja de balance


Descubre empresas con salud financiera